Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Current Management and Future Options for Tardive Dyskinesia

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Psoriasis Treatments

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Advanced Soft Tissue Sarcoma: Current and Future

Atopic Dermatitis Treatment Landscape

Mid-Year Hemophilia Update

What's on the Horizon for Soft Tissue Sarcoma?

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Talking With Your Patients About Excessive Sweating

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Molecular Testing in Ovarian Cancer: Is the Time Now?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Prioritizing Prevention of HPV-Related Disease

The Psychiatrist's Role in Tardive Dyskinesia

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Sarcoma Overview

Case Presentation

Case Presentation (cont)

Case Presentation (cont)

Treatment Options

Olaratumab Phase 2 Results

Adverse Events With Olaratumab Plus Doxorubicin Versus Doxorubicin Alone

Treatment Options (cont)

Importance of Multidisciplinary Team in Sarcoma Diagnosis and Treatment Planning

Case Presentation (cont)

Case Presentation (cont)

Second-Line Treatment Options

Case Presentation (cont)

What to Do Next?

PALETTE Study of Pazopanib

Phase 3 Study of Eribulin

NCCN Guidelines for Soft-Tissue Sarcoma Subtypes With Nonspecific Histologies: Combination Regimens

NCCN Guidelines for Soft-Tissue Sarcoma Subtypes With Nonspecific Histologies: Single Agents

Mutations in Soft-Tissue Sarcomas

The Most Common Histologies

The 10 Most Frequently Mutated Genes

Most Frequently Amplified and Deleted Genes

Checkpoint Inhibitors for Soft-Tissue Sarcomas?

TRK Inhibitor Larotrectinib

Take-Home Messages

Abbreviations

Abbreviations (cont)